Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease (Q36808226)

16 August 2017

Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease (English)

1 reference

16 August 2017

1 reference

Marie-Claire Gubler

4

0 references

Einar Svarstad

series ordinal

2

object named as

Einar Svarstad

1 reference

16 August 2017

5

Camilla Tøndel

1 reference

16 August 2017

3

Leif Bostad

1 reference

16 August 2017

Behzad Najafian

1

1 reference

16 August 2017

Chester Whitley

series ordinal

6

1 reference

16 August 2017

Michael Mauer

series ordinal

7

1 reference

16 August 2017

language of work or name

English

0 references

publication date

15 December 2010

1 reference

16 August 2017

1 reference

16 August 2017

79

1 reference

16 August 2017

6

1 reference

16 August 2017

663-670

1 reference

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Decreased nitric oxide bioavailability in a mouse model of Fabry disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Agalsidase alfa and kidney dysfunction in Fabry disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Albumin excretion rate in normal adolescents: relation to insulin resistance and cardiovascular risk factors and comparisons to type 1 diabetes mellitus patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

High incidence of later-onset fabry disease revealed by newborn screening

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

The podocyte's response to injury: role in proteinuria and glomerulosclerosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Early renal changes in hemizygous and heterozygous patients with Fabry's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

The efficiency of systematic sampling in stereology and its prediction.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Widening of foot processes in normoalbuminuric adolescents with type 1 diabetes

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Assessment of proteinuria using random urine samples.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3640823

Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry's disease

5 September 2018

1 reference

12 December 2020

Progression of glomerular diseases: is the podocyte the culprit?

1 reference

12 December 2020

[Fabry's disease in children. Clinical and biological study of one family. Structure and ultrastructure of the kidney in a hemizygote and a heterozygote]

1 reference

12 December 2020

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

12 December 2020

Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy

1 reference

12 December 2020

Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria

1 reference

12 December 2020

Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports

1 reference

12 December 2020

Newborn screening for lysosomal storage disorders

1 reference

12 December 2020

Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes

1 reference

12 December 2020

Glomerular structure in the normal human kidney: differences between living and cadaver donors

1 reference

12 December 2020

Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes

1 reference

12 December 2020

Early renal failure in Fabry's disease

1 reference

12 December 2020

[Fetal pathology in Fabry's disease and mucopolysaccharidosis type I]

1 reference

12 December 2020

The renal lesion in angiokeratoma corporis diffusum

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FKI.2010.484

7 January 2021

inferred from DOI database lookup

Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FKI.2010.484

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/KI.2010.484

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

21160462

1 reference